FY2025 EPS Estimates for Surmodics Lowered by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research cut their FY2025 earnings estimates for Surmodics in a research report issued to clients and investors on Tuesday, July 1st. Zacks Research analyst D. Dey now anticipates that the company will post earnings of ($0.56) per share for the year, down from their prior estimate of ($0.54). The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.18) EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at ($0.09) EPS.

A number of other brokerages have also recently weighed in on SRDX. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Friday, March 7th.

Surmodics Price Performance

Shares of Surmodics stock traded up $0.99 on Thursday, hitting $29.99. The company's stock had a trading volume of 140,852 shares, compared to its average volume of 229,119. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27. Surmodics has a 52-week low of $26.00 and a 52-week high of $42.44. The firm has a fifty day moving average price of $28.87 and a 200-day moving average price of $31.95. The company has a market capitalization of $428.79 million, a P/E ratio of -21.57 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The business had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative net margin of 16.34% and a negative return on equity of 7.10%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc raised its stake in Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after purchasing an additional 880 shares during the last quarter. Strs Ohio acquired a new position in shares of Surmodics during the 1st quarter worth about $122,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Surmodics during the fourth quarter worth about $217,000. Polymer Capital Management US LLC bought a new stake in shares of Surmodics in the fourth quarter valued at about $255,000. Finally, DeepCurrents Investment Group LLC bought a new position in Surmodics in the fourth quarter valued at $260,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).